- Eliquis (Apixaban) Approved In Europe - A Blockbuster Opportunity For Bristol-Myers, Pfizer
- Forxiga For Type 2 Diabetes Is A Potential Blockbuster - Buy AstraZeneca
- Novartis: Breaking Conglomerate Structure Could Unlock 50-60% Shareholder Returns
- Buy Roche Ahead Of ESMO
- Merck - Invest For A 20 To 40 Percent Return Over The Next 2 Years
Eight years of experience as a sell side analyst covering the Large Cap Pharma sector .
- Description: Sell side analyst. Trading frequency: Infrequent
- Interests: Stocks - long
PharmaIntellect PharmaIntellect – a provider of Global pharmaceutical Intelligence established in 2011 is promoted a by a group of equity research analysts covering different geographies of the global pharmaceutical industry. The pharmaceutical industry is really global in nature and companies / investor need to be aware of ...More
the global dynamics to take prudent decisions. The level of complexity of the pharmaceutical industry is very high due to a very strong regulatory influence on the sector, which gets further complex because of vast number of therapy areas which are mini industries within the pharmaceutical sector. To address these complexities, PharmaIntellect is focused on providing intelligence on the changing market and regulatory dynamics within the sector, which would be highly appreciated by industry and fund managers for decision making
Global Pharmaceutical Intelligence PharmaIntellect.com is an online publication targeted to provide global pharmaceutical intelligence to Industry professionals and Pharma focused fund managers. Drug Sales forecasting and Therapeutic value assessment are the key strengths of PharmaIntellect team We work on a retainer basis for Generic Pharma ...More
companies to help them in their product selection for the US markets. For fund managers and Private Equity companies, we work as independent advisors and partner with them in their investment decisions in the Pharma space.
Currently, there are no book details for Pharma Intelligence.
Latest Comments more »
- Teva would be the first com... on Teva Pharmaceutical Industries' CEO Discusses 2...
- Filing in the US will happe... on Forxiga For Type 2 Diabetes Is A Potential Bloc...
- Besides a flourishing brand... on After two years of under-performance shares of ...
- I entirely agree with you..... on Forxiga For Type 2 Diabetes Is A Potential Bloc...
- The patent expiry pain is t... on New Competition Could Drive Novartis Shares Down
Latest comments on Pharma's Articles
- very_thirsty_for_i... on Forxiga For Type 2 Diabetes Is A Potential Bloc...
- spute on Eliquis (Apixaban) Approved In Europe - A Block...
- Pharma Intelligence on Forxiga For Type 2 Diabetes Is A Potential Bloc...
- dailyrx on Forxiga For Type 2 Diabetes Is A Potential Bloc...
- who noze on Eliquis (Apixaban) Approved In Europe - A Block...
LATEST ARTICLES & INSTAPOSTS more »